Edesa Biotech and Stellar Biotechnologies Complete Business Combination PR Newswire TORONTO, June 7, 2019 TORONTO, June 7, 2019 /PRNewswire/ -- Edesa Biotech, Inc., a clinical-stage...
Stellar Biotechnologies Reports Second Quarter Financial Results PR Newswire LOS ANGELES, May 8, 2019 LOS ANGELES, May 8, 2019 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a...
Stellar Biotechnologies and Edesa Biotech Sign Share Exchange Agreement PR Newswire LOS ANGELES, March 8, 2019 LOS ANGELES, March 8, 2019 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq:...
Stellar Biotechnologies Reports First Quarter Financial Results PR Newswire LOS ANGELES, Feb. 5, 2019 LOS ANGELES, Feb. 5, 2019 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a...
Stellar Biotechnologies Reports Fiscal Year 2018 Financial Results PR Newswire LOS ANGELES, Nov. 30, 2018 LOS ANGELES, Nov. 30, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT...
Stellar Biotechnologies to Present at BlueTech Summit PR Newswire LOS ANGELES, Oct. 31, 2018 LOS ANGELES, Oct. 31, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading...
Stellar Biotechnologies to Supply KLH to National Institutes of Health PR Newswire LOS ANGELES, Sept. 5, 2018 LOS ANGELES, Sept. 5, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq:...
Stellar Biotechnologies to Present at H. C. Wainwright Global Investment Conference PR Newswire LOS ANGELES, Aug. 28, 2018 LOS ANGELES, Aug. 28, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc...
Stellar Biotechnologies Reports Third Quarter Financial Results PR Newswire LOS ANGELES, Aug. 8, 2018 LOS ANGELES, Aug. 8, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a...
Stellar Issues Statement on Favorable Clinical Study Results PR Newswire LOS ANGELES, July 5, 2018 LOS ANGELES, July 5, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales